Provided by Tiger Trade Technology Pte. Ltd.

Humacyte, Inc.

0.6622
+0.02003.11%
Post-market: 0.66780.0056+0.85%19:47 EDT
Volume:3.76M
Turnover:2.51M
Market Cap:184.09M
PE:-1.33
High:0.6936
Open:0.6750
Low:0.6424
Close:0.6422
52wk High:2.55
52wk Low:0.5261
Shares:278.00M
Float Shares:245.00M
Volume Ratio:0.31
T/O Rate:1.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4975
EPS(LYR):-0.2582
ROE:-547.87%
ROA:-49.87%
PB:5.89
PE(LYR):-2.56

Loading ...

Humacyte Plans FDA Filing for Acellular Tissue Engineered Vessel in Dialysis Access

MT Newswires Live
·
Yesterday

Humacyte Says Phase 3 V012 Trial Shows ATEV Extends Catheter-Free Dialysis Time in Women

Reuters
·
Yesterday

Humacyte - Seeks to Add Dialysis Access as Second Approved Indication for Atev

THOMSON REUTERS
·
Yesterday

Humacyte - Supplemental Bla to be Supported by Three Phase 3 Studies of Atev

THOMSON REUTERS
·
Yesterday

Humacyte - to File Supplemental Bla with FDA for Atev in Dialysis Access in November 2026

THOMSON REUTERS
·
Yesterday

Humacyte Confirms Plans for Atev Supplemental Bla Filing for Dialysis Access Following FDA Discussions

THOMSON REUTERS
·
Yesterday

Humacyte Director Keith Anthony Jones Reports Purchase of 10,000 Common Shares Worth $6,930

Reuters
·
Aug 22

Humacyte Director Keith Anthony Jones Acquires 30,000 Shares Worth $17,820

Reuters
·
Aug 20

Humacyte Says Phase 3 V007 Trial Results Show ATEV Tops Fistula for Hemodialysis Access at One Year

Reuters
·
Aug 19

Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results

THOMSON REUTERS
·
Aug 19

Humacyte Faces Nasdaq Non-Compliance Warning as Share Price Risks Delisting and Future Capital Constraints

TIPRANKS
·
Aug 14

U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte

Reuters
·
Aug 13

Humacyte Falls After Wider-than-Expected Quarterly Loss

Reuters
·
Aug 12

Humacyte Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

Humacyte Q2 Net Loss Widens on Inventory, Production Costs

Reuters
·
Aug 12

Humacyte Q2 EPS $(0.16) Misses $(0.10) Estimate, Sales $406.000K Miss $1.116M Estimate

Benzinga Earnings
·
Aug 12

Humacyte Q2 Cash & Investments USD 80.3 Million

THOMSON REUTERS
·
Aug 12

Humacyte Q2 Basic EPS USD -0.16

THOMSON REUTERS
·
Aug 12

Humacyte Q2 Operating Expenses USD 27.402 Million

THOMSON REUTERS
·
Aug 12

Humacyte Q2 Revenue USD 406 Thousand VS. Ibes Estimate USD 1.12 Million

THOMSON REUTERS
·
Aug 12